Medpace Holdings, Inc. Common Stock (MEDP)
Medpace Holdings, Inc. is a global contract research organization (CRO) that provides comprehensive clinical development services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace specializes in conducting clinical trials across various therapeutic areas, offering expertise in regulatory affairs, data management, and project management to support drug development and approval processes.
Company News
The global clinical trial biorepository and archiving solutions market is projected to grow from USD 4.76 billion in 2025 to USD 9.69 billion by 2034, with a CAGR of 8.21%. North America dominates the market, while Asia Pacific is expected to experience the fastest growth, driven by advancements in biobanking technologies and increasing demand for personalized medicine.
Medpace, a clinical contract research organization, reported strong Q2 2025 earnings, exceeding analyst expectations with 14.2% revenue growth and raised full-year guidance despite sector challenges.
The article compares the valuation metrics of HealthEquity (HQY) and Medpace (MEDP) to determine which stock is the better value option. Based on factors like Zacks Rank, forward P/E, and PEG ratio, the article concludes that HQY is the superior value option.
The article compares Surgery Partners (SGRY) and Medpace (MEDP) to determine which is the better value stock. It analyzes various valuation metrics and concludes that SGRY is the superior value option based on its improving earnings outlook and more favorable valuation metrics.
